Mycosis fungoides is one of the most common forms of cutaneous T-cell lymphoma. Its diagnosis is sometimes challenging and quite difficult for the physician, because its onset clinical appearance is similar to other skin diseases. Although there are a few hypotheses about mycosis fungoides’ etiology, they aren’t fully understood and still need confirmation. We report the case of a 68 years old patient diagnosed with mycosis fungoides, who has been exposed to asbestos fibers. This case is one of the few reported cases of association between asbestos and mycosis fungoides. There is no data exploring the causal relation between asbestos exposure and mycosis fungoides but common biological mechanisms could represent an argument. If occupational exposure to asbestos will be confirmed in larger studies, a new research-field of asbestos-related diseases needs to be opened.
1.Ortonne N: Update on cutaneous lymphomas. Diagnostic histopathology 2018;24:301-12.
2.Jawed SI, Myskowski PL, Horwitz S. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014;70:205-e1.
3. Beyer M, Möbs M, Humme D, Sterry W. Pathogenese der Mycosis fungoides. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2011;9:594-9.
4.A. Kelati et al, Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis, International Journal of Women’s Dermatology, 2017, vol 3(2): 100-106.
5.Kelati A, Gallouj S, Tahiri L. Defining the mimics and clinicohistological diagnosis criteria for mycosis fungoides to minimize misdiagnosis. Int J Womens Health 2017;3:100-6.
6.Willemze R, Meijer CJ.. Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. J Cutan Pathol 2006;33:18–26.
7.Krejsgaard T, Odum N, Geisler C. Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia 2012;26:424.
8.Saed G, Fivenson DP, Naidu Y. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. J Invest Dermatol 1994; 103:29–33.
9.Olek-Hrab K, Silny W. Diagnostics in mycosis fungoides and Sezary syndrome. Reports of Practical Oncology & Radiotherapy 2014;19:72-6.
10.Al Hothali GI. Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach, Int J Health Sci (Qassim) 2013;7: 220–39.
11.Morales-Suárez-Varela MM, Olsen J, Johansen P. Occupational risk factors for mycosis fungoides: a European multicenter case-control study, J Occup Environ Med.2004; 46:205-11.
12.Slodownik D, Moshe S, Sprecher E. Occupational mycosis fungoides - a case series. Int J Dermatol 2017; 56:733-37.
13. Mortazavi H, Firouzabadi LI, Ghanadan A. Occurrence of Mycosis Fungoides in an Iranian Chemical Victim of the Iran-Iraq War with a Long-term Follow-Up: A Case Report and Review of Literature. Iran J Med Sci 2018;43:324.
14.Bianchi C, Bianchi T. Non-Hodgkin lymphoma and pleural mesothelioma in a person exposed to asbestos. Turk Patoloji Derg. 2018;34:190-3.
15.Chirinos R, Geskin L. Coexistence of mycosis fungoides and malignant mesothelioma in two patients from the same geographic area. J Am Acad Dermatol 2008;58:suppl2:AB77.
16.IARC Monographs on the Evalation of Carcinogenic risks to Human. Handbooks of Cancer Prevention. Available: https://monographs.iarc.fr [Accessed on 12.10.2018].
17.Matsuzaki H, Maeda Megumi, Suni Lee. Asbestos-Induced Cellular and Molecular Alteration of Immunocompetent Cells and Their Relationship with Chronic Inflammation and Carcinogenesis. J Biomed Biotechnol 2012:9.
18.Naofumi Hara, Nobukazu Fujimoto, Yosuke Miyamoto. Lymphoproliferative disorder in pleural effusion in a subject with past asbestos exposure. Respir Med Case Rep 2015; 16:169-71.
19.Agency for Toxic Substances and Disease Registry. Toxicological Profile for Asbestos. Atlanta, GA: Agency for Toxic Substances and Disease Registry; 2001. Available: http://www.atsdr.cdc.gov/toxprofiles/tp61.html [Accessed on 15.11.2018].
20.Naghi E, Rascu A. Pneumoconioze, in Pneumologie, sub redactia Miron Alexandru Bogdan Ed.Universitara “Carol Davila”, Bucuresti, 2008, 291-303.
21.Maeda M, Nishimura Y, Kumagai N. Dysregulation of the immune system caused by silica and asbestos. J Immunotoxicol 2010;7:268-78.
22.Nisimura Y, Kumagai-Takei N, Matsuzaki H. Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients. Biomed Res Int 2015;2015:238431.
23. Kumagai-Takei N, Nishimura Y, Maeda M. Functional Properties of CD8. J Immunol Res. 2014;2014.
24.Becker N, Berger J, Bolm-Audorff U. Asbestos exposure and malignant lymphomas-a review of the epidemiological literature. Int Arch Occup Environ Health 2001;74:459-69).
25.Tan RS, Butterworth, McLaughlin H. Mycosis fungoides - a disease of antigen persistence. Br J Dermatol. 1974;91:607-16.
26.Stadler R, Stranzenbach R. Molecular pathogenesis of cutaneous lymphomas. Exp. Dermatol 2018;27:1078-83.
27.Lange A, Skibiński G, Garncarek D. The Follow-Up Study of Skin Reactivity to Recall Antigens and E- and EAC-RFC Profiles in Blood in Asbestos Workers. Immunobiology 1980:157:1-11.
28.Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk 2012;12:291-6.